scholarly journals Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor

2014 ◽  
Vol 136 (2) ◽  
pp. 333-339 ◽  
Author(s):  
Niek Hugen ◽  
Rob H. Verhoeven ◽  
Valery E Lemmens ◽  
Carola J. van Aart ◽  
Marloes A. Elferink ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Poor Prognostic Factor ◽  
Signet Ring ◽  
Ring Cell

Colorectal signet-ring cell carcinoma: Responsive to adjuvant chemotherapy but still a poor prognosis.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 529-529
Author(s):  
Niek Hugen ◽  
Rob H. A. Verhoeven ◽  
Valery E. P. P. Lemmens ◽  
Carola J. C. Van Aart ◽  
Marloes A. G. Elferink ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Treatment Guidelines ◽  
Relative Survival ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Prognostic Impact ◽  
Colon And Rectal Cancer ◽  
Signet Ring ◽  
Ring Cell

529 Background: Colorectal signet-ring cell carcinoma (SRCC) has been associated with a poor survival compared to mucinous adenocarcinoma (MC) and the common adenocarcinoma (AC). Prognostic impact of tumor localization is unknown and efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyses prognostic impact of SRCC and determines whether SRCC patients benefit from adjuvant chemotherapy for colon cancer equally compared with AC. Methods: Data on 196,757 patients with CRC in the Netherlands in the period 1989 and 2010 was included in this nationwide population-based study. Five-year relative survival estimates were calculated and multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) were performed. Results: SRCC was found in 1.0% of CRC patients. SRCC patients presented more frequently with stage III or IV disease than AC (75.2% versus 43.6%, P<0.0001) and SRCC was more frequently found in the proximal colon (57.7% versus 32.0%, P<0.0001). SRCC patients had a poor 5-year relative survival of 31% in colon and 20% in the rectum compared to 57% and 59% in AC (P<0.0001). This poorer survival for SRCC was found in stage II, III and IV. In comparison with AC, there was no significant interaction between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81-1.51), suggesting a comparable benefit from adjuvant chemotherapy in AC and SRCC. Conclusions: Prognostic impact of SRCC is dismal in both colon and rectal cancer patients, but colonic SRCC patients seem to benefit from adjuvant chemotherapy equally compared with AC. Reduced efficacy of adjuvant chemotherapy therefore does not seem to explain the poor outcome in SRCC patients. We recommend to adhere to adjuvant treatment guidelines for all histological subtypes, but encourage clinical trials to take histological subtype into account for stratification.

scholarly journals Clinical Characteristics and Prognostic Analysis of Patients With Signet Ring Cell Gastric Carcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382098381
Author(s):  
Jia Mi Yu ◽  
Zhou Wei Zhan ◽  
Jing Xian Zhen ◽  
Xiao Jie Wang ◽  
Yu Chen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Gastroesophageal Junction ◽  
Tumor Stage ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Signet Ring ◽  
Ring Cell

We do not know the clinical and prognostic factors that influence the survival of patients with gastric signet ring cell carcinoma (SRC). Therefore, a retrospective review was undertaken of 219 patients with SRC who had undergone gastrectomy between January 2009 and December 2012 in our hospital. Patient age, sex, TNM stage, vessel carcinoma embolus, perineural invasion, tumor site and operation type, postoperative chemotherapy, and five-year overall survival were recorded and evaluated. In our study, 93 cases (42.5%) were signet ring cell carcinoma only, and 126 cases (57.5%) were signet ring cell carcinoma coexisting with other components (such as adenocarcinoma or mucus adenocarcinoma). Eighty-three patients were female, 136 were male, 46 occurred at the gastroesophageal junction (21.0%), 63 at the fundus/body (28.8%), 80 were antrum/pylorus (36.5%), and 30 were whole stomach (13.7%). The prognosis of gastric antrum/ pylorus cancer was the best (P < 0.05). There were 133 patients (60.7%) with stage III, and the single factor analysis showed that the earlier the stage, the better the prognosis. The overall five-year survival rate was 30.1% in all patients. One-hundred and 41 patients (64.4%) received D2 radical surgery, 64 (29.2%) received D1 radical operation, and 14 (6.4%) received palliative resection, and the patients who received D2 had the best overall survival (P < 0.05). The survival time of the paclitaxel-based regimen in postoperative adjuvant chemotherapy tended to be prolonged. There was no statistical difference in overall survival between the percentage of signet-ring cells and sex. In summary, age, tumor stage, and surgical resection combined with D2 lymphadenectomy were independent prognostic factors for SRC. Adjuvant chemotherapy with a paclitaxel-based regimen may improve the survival of patients with SRC.

scholarly journals Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Takashi Hamakawa ◽  
Yoshiyuki Kojima ◽  
Taku Naiki ◽  
Yasue Kubota ◽  
Takahiro Yasui ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Urinary Bladder ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Term Survival ◽  
Signet Ring ◽  
Ring Cell

Primary signet-ring cell carcinoma of the urinary bladder is extremely rare and patient survival is very poor. The disease usually presents at advanced stages because the cancer progresses rapidly. The only option for effective treatment is radical cystectomy, and no effective chemotherapy has been established for this variant. We report a case of signet-ring cell carcinoma of the urinary bladder with a long-term survival of 90 months owing to radical cystectomy and combination adjuvant chemotherapy with S-1 and cisplatin. To our knowledge, this is the first report to demonstrate the long-term therapeutic activity of combination S-1 and cisplatin adjuvant chemotherapy against invasive signet-ring cell carcinoma of the urinary bladder.

scholarly journals The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Zhuang Zhao ◽  
Na Yan ◽  
Shu Pan ◽  
Dun-wei Wang ◽  
Zhi-wen Li
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Stage Ii ◽  
Signet Ring ◽  
Ring Cell

scholarly journals Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

2020 ◽  
Author(s):  
Akihiko Takagi ◽  
Satoshi Tokuda ◽  
Takeo Toda ◽  
Kazuya Higashizono ◽  
Keisei Taku ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Portal Vein ◽  
Cell Carcinoma ◽  
Signet Ring Cell Carcinoma ◽  
Good Prognosis ◽  
Signet Ring Cell ◽  
Term Survival ◽  
Signet Ring ◽  
Ring Cell ◽  
One Year

Abstract Background: Signet ring cell carcinoma (SRCC) of the pancreas is a very rare histologic variant of pancreatic carcinoma with very poor prognosis. We present a case of pancreatic SRCC with good prognosis achieved by resection and adjuvant chemotherapy with S-1 one year, which is the standard treatment for advanced resected gastric cancer in Japan. The stomach carried a higher incidence of SRCC than other sites.Case presentation: A 70-year-old man presented with abdominal discomfort, and ultrasonography revealed a mass in the pancreas. Computed tomography showed a hypovascular tumor in the head of the pancreas, 51 mm in diameter, with invasion to the portal vein and duodenum. The patient underwent pancreaticoduodenectomy (PD) with portal vein resection and reconstruction. The pathological diagnosis was SRCC of the pancreas without invasion to the portal vein, pT3N1M0 Stage IIB (UICC classification). Subsequently, postoperative adjuvant chemotherapy with S-1 was initiated to prevent recurrence. The patient has remained recurrence-free for 2 years and 6 months after PD. Conclusion: Adjuvant chemotherapy with S-1 may be an important factor for improving the prognosis of patients with resectable SRCC of the pancreas.

scholarly journals Adverse Histological Features Alone Was Not Sufficient for Decision of Adjuvant Chemotherapy in T3N0M0 colonic cancer: A Propensity Score Matching Study Based on Population Analysis

2021 ◽  
Author(s):  
Qinghua Wang ◽  
Hongjuan Zheng ◽  
Xiaoxiao Chen ◽  
Xia Zhang ◽  
Xiayun Jin ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
Cell Carcinoma ◽  
Mucinous Adenocarcinoma ◽  
Survival Benefit ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Histological Features ◽  
Signet Ring ◽  
Ring Cell

Abstract Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Approximately 25% of patients with AJCC stage II suffered recurrence after radical surgery, but the role of adjuvant chemotherapy in Stage II CRC is controversial. We aimed to evaluate the benefit from chemotherapy for T3N0M0 patients with adverse histological features. Methods: An analysis of the Surveillance, Epidemiology, and End Results (SEER) 18 databases was performed to identify patients underwent radical resection 20-80 years old with colonic carcinoma diagnosed during year 2004 to 2012. Poorly differentiated, undifferentiated, mucinous adenocarcinoma and signet ring cell carcinoma (SRCC) were defined as adverse histological features, and well or moderately differentiated adenocarcinoma as good histological features. Multivariate analyses were used to adjust the effects of other covariates. The survival benefit of adjuvant chemotherapy was demonstrated in the propensity score matching cohort. Results: The adjuvant chemotherapy brought no survival benefit (good histological features HR, 1.076; 95% CI, 0.957-1.211; P=0.220; adverse histological features HR, 0.995; 95% CI, 0.777-1.274; P=0.967); Neither mucinous adenocarcinoma nor signet ring cell carcinoma brought a significance on survival (mucinous adenocarcinoma HR, 0.699; 95% CI, 0.488-1.002; P=0.051; signet ring cell carcinoma HR, 0.750; 95% CI, 0.386-1.459; P=0.397) compared to adenocarcinoma. Left-side colon was associated with a poorer survival in good histological features group (HR, 1.136; 95% CI, 1.034-1.248; P=0.008). Conclusions: The adverse histological features don’t influence on survival for patients with T3N0M0 staging, and adjuvant chemotherapy is invalid to improve the survival for these patients, indicating adverse histological features alone was not sufficient for decision of adjuvant chemotherapy in this situation rather than the recommendation of the guidelines.

Sign in / Sign up

Export Citation Format

Share Document